Welcome to our dedicated page for BeOne Medicines Ltd. SEC filings (Ticker: ONC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BeOne Medicines Ltd. (ONC) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8‑K and other documents filed with the Securities and Exchange Commission. BeOne is a Switzerland‑domiciled global oncology company whose American Depositary Shares are registered with the SEC, while its ordinary shares trade on the Hong Kong Stock Exchange and it also reports to the STAR Market in Shanghai.
Through its filings, BeOne reports on financial results, material agreements and corporate events. Recent Forms 8‑K referenced in the input include announcements of quarterly financial results, describing revenue growth driven primarily by BRUKINSA product sales and contributions from TEVIMBRA and in‑licensed products. Other 8‑K filings detail a royalty purchase agreement with Royalty Pharma tied to royalty rights on IMDELLTRA (tarlatamab) ex‑China net revenue, as well as the creation of related financial obligations and escrow arrangements.
Additional 8‑K reports cover topics such as the termination of a prior credit facility after arranging new financing, and the appointment and compensation terms of senior research and development leadership. The company also furnishes information about its interim reports filed with the STAR Market, including financial data prepared under China Accounting Standards and summaries of differences from U.S. GAAP.
On Stock Titan, users can review these ONC filings alongside AI‑generated summaries that explain the main points of each document in plain language. This includes highlighting key items in earnings‑related filings, summarizing the structure and implications of material agreements, and pointing out governance or leadership changes disclosed under Item 5.02 of Form 8‑K. Investors can also use the filings page to monitor how BeOne describes its oncology portfolio, collaborations and financial position over time, and to cross‑reference U.S. disclosures with the company’s press releases and non‑U.S. reporting.
Real‑time updates from EDGAR, combined with AI‑assisted overviews, help readers navigate lengthy filings and focus on sections most relevant to their interests, whether they are following BeOne’s hematology and solid tumor programs, its financing arrangements or its multi‑exchange reporting obligations.
BeOne Medicines (ONC) – Form 4 insider activity
Chief Financial Officer Aaron Rosenberg reported a mandatory tax-related sale of 1,190 American Depositary Shares (ADS) on 08/01/2025 at $290.47 per ADS, generating roughly $0.35 million in proceeds. Each ADS represents 13 ordinary shares. The disposition was executed automatically to cover withholding taxes triggered by the vesting of a restricted share-unit (RSU) grant. One-quarter of the RSU award vests annually on 31 July through 2028, with accelerated vesting possible upon certain termination events.
No derivative securities were exercised or disposed of in this filing. After the transaction, Rosenberg directly owns 215,332 ordinary shares and 0 ADS, meaning the shares sold equal about 7 % of his reported equity stake. The filing shows continued equity alignment through ongoing RSU vesting, while the share sale itself may be viewed as a routine liquidity event rather than an indicator of fundamental outlook.
BeOne Medicines Ltd. (ONC) – Form 4 filing dated 31-Jul-2025
SVP & General Counsel Henry Chan Lee reported a mandatory tax-related sale of 920 American Depositary Shares (ADS) on 30-Jul-2025 at a weighted-average price of $304.6008. Each ADS equals 13 ordinary shares, so the transaction represents the disposition of roughly 11,960 ordinary shares equivalent.
The ADS were automatically sold to cover withholding taxes upon vesting of a previously granted RSU award that vests 25 % annually on the anniversary of 29-Jul-2022, with possible acceleration on certain termination events. Following the sale, Lee continues to hold 266,474 ordinary shares directly.
- No derivative security activity was reported.
- The filing was executed by attorney-in-fact Qing Nian.
The transaction appears routine and driven by tax-withholding obligations rather than discretionary selling, limiting its market significance.